Staging the axilla in breast cancer patients with 18F-FDG PET: How small are the metastases that we can detect with new generation clinical PET systems?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 6, 2014, Pages 1103-1112

  Bellevre, Dimitri ^a   Blanc Fournier, Cécile ^a   Switsers, Odile ^a   Dugué, Audrey Emmanuelle ^a   Levy, Christelle ^a   Allouache, Djelila ^a   Desmonts, Cédric ^b   Crouet, Hubert ^c   Guilloit, Jean Marc ^c   Grellard, Jean Michel ^a   Aide, Nicolas ^a,d  

^a Haematology Institute   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c Surgical Oncology François Baclesse Cancer Centre   (France)

^d NORMANDIE UNIVERSITÉ   (France)

Author keywords

Axillary staging; Breast cancer; Fluorodeoxyglucose; PET CT; PSF reconstruction

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ALGORITHM; ARTICLE; AXILLA; AXILLARY LYMPH NODE EXTIRPATION; AXILLARY LYMPH NODE METASTASIS; AXILLARY STAGING; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FEMALE; FUNCTION TEST; HUMAN; IMAGING PHANTOM; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; OSEM ALGORITHM; POINT SPREAD FUNCTION; PREDICTIVE VALUE; PRIMARY TUMOR; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURGICAL APPROACH; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; IMAGE PROCESSING; LIMIT OF DETECTION; MIDDLE AGED; MULTIMODAL IMAGING; PAGET NIPPLE DISEASE; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; SECONDARY; VALIDATION STUDY;

ALGORITHMS; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIMIT OF DETECTION; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84900821990     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2689-7     Document Type: Article

References (31)

1. Groheux D, Espie M, Giacchetti S, Hindie E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266:388-405.
2. Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543-50.
3. Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, et al. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:32-40.
4. Straver ME, Aukema TS, Olmos RA, Rutgers EJ, Gilhuijs KG, Schot ME, et al. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging. 2010;37:1069-76.
5. Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging. 2012;39:1618-27.
6. Cooper KL, Harnan S, Meng Y, Ward SE, Fitzgerald P, Papaioannou D, et al. Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2011;37:187-98.
7. Andersen FL, Klausen TL, Loft A, Beyer T, Holm S. Clinical evaluation of PET image reconstruction using a spatial resolution model. Eur J Radiol. 2013;82:862-9.
8. Lasnon C, Hicks RJ, Beauregard JM, Milner A, Paciencia M, Guizard AV, et al. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer. Clin Nucl Med. 2012;37:971-6.
9. Aide N, Desmonts C, Beauregard JM, Beyer T, Kinross K, Roselt P, et al. High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. Eur J Nucl Med Mol Imaging. 2010;37:991-1001.
10. Kadrmas DJ, Casey ME, Conti M, Jakoby BW, Lois C, Townsend DW. Impact of time-of-flight on PET tumor detection. J Nucl Med. 2009;50:1315-23.
11. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200.
12. Brambilla M, Secco C, Dominietto M, Matheoud R, Sacchetti G, Inglese E. Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med. 2005;46:2083-91.
13. Black WC, Armstrong P. Communicating the significance of radiologic test results: the likelihood ratio. AJR Am J Roentgenol. 1986;147:1313-8.
14. Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet. 2005;365:1500-5.
15. Groheux D, Hindie E, Rubello D, Espie M, Baillet G, Giacchetti S, et al. Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging. 2009;36:1539-42.
16. Biggerstaff BJ. Comparing diagnostic tests: a simple graphic using likelihood ratios. Stat Med. 2000;19:649-63.
17. Jakoby BW, Bercier Y, Conti M, Casey ME, Bendriem B, Townsend DW. Physical and clinical performance of the mCT time-of-flight PET/CT scanner. Phys Med Biol. 2011;56:2375-89.
18. Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PETCT Discovery-690. Med Phys. 2011;38:5394-411.
19. Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, et al. Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Ann Surg Oncol. 2012;19:1808-17.
20. Kuru B, Camlibel M, Dinc S, Gulcelik MA, Alagol H. Prognostic significance of axillary node and infraclavicular lymph node status after mastectomy. Eur J Surg Oncol. 2003;29:839-44.
21. Aukema TS, Straver ME, Valdes Olmos RA, Vogel WV. A different role for FDG PET/CT in axillary lymph node staging in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1896-7.
22. Chua S, Groves AM. Pretreatment PET in breast cancer: is there a role? Eur J Nucl Med Mol Imaging. 2012;39:1827-9.
23. Gilardi L, De Cicco C, Paganelli G. Preoperative FDG PET/CT in breast cancer patients: where are we going? Eur J Nucl Med Mol Imaging. 2012;39:1667-9.
24. Akamatsu G, Ishikawa K, Mitsumoto K, Taniguchi T, Ohya N, Baba S, et al. Improvement in PET/CT image quality with a combination of point-spread function and time-of-flight in relation to reconstruction parameters. J Nucl Med. 2012;53:1716-22.
25. Akamatsu G, Mitsumoto K, Ishikawa K, Taniguchi T, Ohya N, Baba S, et al. Benefits of point-spread function and time of flight for PET/CT image quality in relation to the body mass index and injected dose. Clin Nucl Med. 2013;38:407-12.
26. Boellaard R. Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl Med. 2011;52 Suppl 2:93S-100S.
27. Boellaard R. Optimisation and harmonisation: two sides of the same coin? Eur J Nucl Med Mol Imaging. 2013;40:982-4.
28. Makris NE, Huisman MC, Kinahan PE, Lammertsma AA, Boellaard R. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging. 2013;40:1507-15.
29. Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, et al. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 2012;53:1337-44.
30. Kelly MD, Declerck JM. SUVref: reducing reconstruction-dependent variation in PET SUV. EJNMMI Res. 2011;1:16.
31. Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985-96.